APOM and high-density lipoprotein cholesterol are associated with lung function and per cent emphysema

European Respiratory Journal

Volumn 43, Issue 4, 2014, Pages 1003-1017

  Burkart, Kristin M ^a   Manichaikul, Ani ^b   Wilk, Jemma B ^c   Ahmed, Firas S ^a   Burke, Gregory L ^d   Enright, Paul ^e   Hansel, Nadia N ^f   Haynes, Demondes ^g   Heckbert, Susan R ^h   Hoffman, Eric A ⁱ   Kaufman, Joel D ^h   Kurai, Jun ^j   Loehr, Laura ^k   London, Stephanie J ^l   Meng, Yang ^m   O'Connor, George T ^n,o   Oelsner, Elizabeth ^a   Petrini, Marcy ^g   Pottinger, Tess D ^a   Powell, Charles A ^j   Redline, Susan ^p   Rotter, Jerome I ^q   Smith, Lewis J ^r   Artigas, María Soler ^s   Tobin, Martin D ^s,t   Tsai, Michael Y ^u   Watson, Karol ^v   White, Wendy ^w   Young, Taylor R ^m   Rich, Stephen S ^b   Barr, R Graham ^a   more..

^a Dept of Medicine College of Physic and Surg Columbia University ^*  (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ UNIVERSITY OF IOWA   (United States)

^j MOUNT SINAI HOSPITAL   (United States)

^k University of North Carolina at Chapel Hill   (United States)

^l NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^m BROAD INSTITUTE OF MIT AND HARVARD   (United States)

ⁿ BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o FRAMINGHAM HEART STUDY   (United States)

^p HARVARD MEDICAL SCHOOL   (United States)

^q CEDARS SINAI MEDICAL CENTER   (United States)

^r NORTHWESTERN UNIVERSITY   (United States)

^s UNIVERSITY OF LEICESTER   (United Kingdom)

^t The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

^u UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^v UNIVERSITY OF CALIFORNIA   (United States)

^w TOUGALOO COLLEGE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN M; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; APOLIPOPROTEIN; APOM PROTEIN, HUMAN; LIPOCALIN;

ADULT; AFRICAN AMERICAN; AGED; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LUNG EMPHYSEMA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PCSK9 GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPIROMETRY; BLOOD; CAUCASIAN; EMPHYSEMA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; LUNG; META ANALYSIS; MIDDLE AGED; PHYSIOLOGY; UNITED STATES; VITAL CAPACITY;

ADULT; AFRICAN AMERICANS; AGED; APOLIPOPROTEINS; CHOLESTEROL, HDL; COHORT STUDIES; EMPHYSEMA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FORCED EXPIRATORY VOLUME; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOTYPE; HUMANS; LIPOCALINS; LUNG; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY; UNITED STATES; VITAL CAPACITY;

EID: 84897470317     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00147612     Document Type: Conference Paper

References (99)

1. Lozano R, Naghavi M, Foreman K., et al Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128.
2. Petty TL, Weinmann GG Building a national strategy for the prevention and management of and research in chronic obstructive pulmonary disease. National Heart, Lung, and Blood Institute Workshop Summary. Bethesda, Maryland, August 29-31, 1995. JAMA 1997; 277: 246-253.
3. Pauwels RA, Buist AS, Calverley P.M., et al Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
4. McLean KH. The pathogenesis of pulmonary emphysema. Am J Med 1958; 25: 62-74.
5. Silverman EK, Chapman HA, Drazen J.M., et al Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 1998; 157: 1770-1778.
6. Silverman EK, Palmer LJ, Mosley J.D., et al Genomewide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. Am J Hum Genet 2002; 70: 1229-1239.
7. McCloskey SC, Patel BD, Hinchliffe S.J., et al Siblings of patients with severe chronic obstructive pulmonary disease have a significant risk of airflow obstruction. Am J Respir Crit Care Med 2001; 164: 1419-1424.
8. Cho MH, McDonald M-LN, Zhou X, et al Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis. Lancet Respir Med 2014 [In press DOI: 10.1016/S2213-2600(14)70002-5].
9. Soler Artigas M., Loth DW, Wain L.V., et al Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet 2011; 43: 1082-1090.
10. Wilk JB, Shrine NR, Loehr L.R., et al Genome-wide association studies identify CHRNA5/3 and HTR4 in the development of airflow obstruction. Am J Respir Crit Care Med 2012; 186: 622-632.
11. Hancock DB, Soler Artigas M, Gharib SA, et al Genome-wide joint meta-analysis of SNP and SNP-by-smoking interaction identifies novel loci for pulmonary function. PLoS Genet 2012; 8: e1003098.
12. Repapi E, Sayers I, Wain L.V., et al Genome-wide association study identifies five loci associated with lung function. Nat Genet 2010; 42: 36-44.
13. Hancock DB, Eijgelsheim M, Wilk J.B., et al Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet 2010; 42: 45-52.
14. Wilk JB, Chen TH, Gottlieb D.J., et al A genome-wide association study of pulmonary function measures in the Framingham Heart Study. PLoS Genet 2009; 5: e1000429.
15. Cho MH, Boutaoui N, Klanderman B.J., et al Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet 2010; 42: 200-202.
16. Soler Artigas M., Wain LV, Repapi E, et al Effect of five genetic variants associated with lung function on the risk of chronic obstructive lung disease, and their joint effects on lung function. Am J Respir Crit Care Med 2011; 184: 786-795.
17. Castaldi PJ, Cho MH, Litonjua A.A., et al The association of genome-wide significant spirometric loci with chronic obstructive pulmonary disease susceptibility. Am J Respir Cell Mol Biol 2011; 45: 1147-1153.
18. Patel BD, Coxson HO, Pillai S.G., et al Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178: 500-505.
19. Kong X, Cho MH, Anderson W, et al Genome-wide association study identifies BICD1 as a susceptibility gene for emphysema. Am J Respir Crit Care Med 2011; 183: 43-49.
20. Manichaikul A, Hoffman EA, Smolonska J, et al Genome-wide Study of Percent Emphysema on CT in the General Population: The MESA Lung/SHARe Study. Am J Respir Crit Care Med 2014 [In press DOI: 10.1164/rccm.201306-1061OC].
21. DeMeo DL, Hersh CP, Hoffman E.A., et al Genetic determinants of emphysema distribution in the National Emphysema Treatment Trial. Am J Respir Crit Care Med 2007; 176: 42-48.
22. Hersh CP, Hansel NN, Barnes K.C., et al Transforming growth factor-b receptor-3 is associated with pulmonary emphysema. Am J Respir Cell Mol Biol 2009; 41: 324-331.
23. Lambrechts D, Buysschaert I, Zanen P., et al The 15q24/25 susceptibility variant for lung cancer and chronic obstructive pulmonary disease is associated with emphysema. Am J Respir Crit Care Med 2010; 181: 486-493.
24. Kim DK, Hersh C, Washko G.R., et al Epidemiology, radiology, and genetics of nicotine dependence in COPD. Respir Res 2011; 12: 9.
25. Yamada M, Ishii T, Ikeda S., et al Association of fucosyltransferase 8 (FUT8) polymorphism Thr267Lys with pulmonary emphysema. J Hum Genet 2011; 56: 857-860.
26. Ishii T, Hagiwara K, Ikeda S., et al Association between genetic variations in surfactant protein D and emphysema, interstitial pneumonia, and lung cancer in a Japanese population. COPD 2012; 9: 409-416.
27. Keating BJ, Tischfield S, Murray S.S., et al Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One 2008; 3: e3583.
28. Giordano RJ, Lahdenranta J, Zhen L., et al Targeted induction of lung endothelial cell apoptosis causes emphysema-like changes in the mouse. J Biol Chem 2008; 283: 29447-29460.
29. Clauss M, Voswinckel R, Rajashekhar G., et al Lung endothelial monocyte-activating protein 2 is a mediator of cigarette smoke-induced emphysema in mice. J Clin Invest 2011; 121: 2470-2479.
30. Barr RG, Bluemke DA, Ahmed F.S., et al Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010; 362: 217-227.
31. Barr RG, Ahmed FS, Carr J.J., et al Subclinical atherosclerosis, airflow obstruction and emphysema: the MESA Lung Study. Eur Respir J 2012; 39: 846-854.
32. Kim JA, Montagnani M, Koh K.K., et al Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113: 1888-1904.
33. Kasahara Y, Tuder RM, Cool C.D., et al Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med 2001; 163: 737-744.
34. Santos S, Peinado VI, Ramirez J, et al Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 1250-1256.
35. Kanazawa H, Asai K, Hirata K., et al Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. Am J Med 2003; 114: 354-358.
36. Leibow AA. Pulmonary emphysema with special reference to vascular changes. Am Rev Respir Dis 1959; 80: 67-93.
37. Barr RG, Mesia-Vela S, Austin J.H., et al Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study. Am J Respir Crit Care Med 2007; 176: 1200-1207.
38. Tuder RM, Petrache I, Elias J.A., et al Apoptosis and emphysema: the missing link. Am J Respir Cell Mol Biol 2003; 28: 551-554.
39. Tuder RM, Zhen L, Cho C.Y., et al Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol 2003; 29: 88-97.
40. Petrache I, Natarajan V, Zhen L., et al Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med 2005; 11: 491-498.
41. Xia P, Vadas MA, Rye K.A., et al High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem 1999; 274: 33143-33147.
42. Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for pre-b-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 2005; 11: 418-422.
43. Christoffersen C, Jauhiainen M, Moser M., et al Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem 2008; 283: 1839-1847.
44. Christoffersen C, Obinata H, Kumaraswamy S.B., et al Endothelium- protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA 2011; 108: 9613-9618.
45. Musunuru K, Lettre G, Young T., et al Candidate gene association resource (CARe): design, methods, and proof of concept. Circ Cardiovasc Genet 2010; 3: 267-275.
46. Bild DE, Bluemke DA, Burke G.L., et al Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 2002; 156: 871-881.
47. The ARIC investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989; 129: 687-702.
48. Fried LP, Borhani NO, Enright P, et al The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991; 1: 263-276.
49. Dawber TR, Kannel WB The Framingham study. An epidemiological approach to coronary heart disease. Circulation 1966; 34: 553-555.
50. Feinleib M, Kannel WB, Garrison R.J., et al The Framingham Offspring Study. Design and preliminary data. Prev Med 1975; 4: 518-525.
51. Friedman GD, Cutter GR, Donahue R.P., et al CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988; 41: 1105-1116.
52. Buxbaum SG, Elston RC, Tishler P.V., et al Genetics of the apnea hypopnea index in Caucasians and African Americans: I. Segregation analysis. Genet Epidemiol 2002; 22: 243-253.
53. Taylor HA Jr. The Jackson Heart Study: an overview. Ethn Dis 2005; 15: Suppl. 6, 1-3.
54. Carpenter MA, Crow R, Steffes M., et al Laboratory, reading center, and coordinating center data management methods in the Jackson Heart Study. Am J Med Sci 2004; 328: 131-144.
55. Rodriguez J, Jiang R, Johnson W.C., et al The association of pipe and cigar use with cotinine levels, lung function, and airflow obstruction: a cross-sectional study. Ann Intern Med 2010; 152: 201-210.
56. Hankinson JL, Odencrantz JR, Fedan KB Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159: 179-187.
57. Manichaikul A, Chen WM, Williams K, et al Analysis of family- and population-based samples in cohort genome-wide association studies. Hum Genet 2012; 131: 275-287.
58. Kaufman JD, Adar SD, Allen R.W., et al Prospective study of particulate air pollution exposures, subclinical atherosclerosis, and clinical cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis and Air Pollution (MESA Air). Am J Epidemiol 2012; 176: 825-837.
59. Hoffman EA, Jiang R, Baumhauer H., et al Reproducibility and validity of lung density measures from cardiac CT scans - the Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study. Acad Radiol 2009; 16: 689-699.
60. Tsai MY, Johnson C, Kao WHL, et al Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2008; 200: 359-367.
61. Purcell S, Neale B, Todd-Brown K, et al PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
62. Chen MH, Yang Q. GWAF: an R package for genome-wide association analyses with family data. Bioinformatics 2010; 26: 580-581.
63. Price AL, Patterson NJ, Plenge R.M., et al Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909.
64. Willer CJ, Li Y, Abecasis GR METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 2010; 26: 2190-2191.
65. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6: 65-70.
66. Pruim RJ, Welch RP, Sanna S, et al LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 2010; 26: 2336-2337.
67. Kappelle PJ, Lambert G, Dahlbäck B, et al Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects. Atherosclerosis 2011; 214: 492-494.
68. Hu HJ, Jin EH, Yim S.H., et al Common variants at the promoter region of the APOM confer a risk of rheumatoid arthritis. Exp Mol Med 2011; 43: 613-621.
69. Xu N, Dahlbäck B. A novel human apolipoprotein (apoM). J Biol Chem 1999; 274: 31286-31290.
70. Nielsen LB, Christoffersen C, Ahnström J, et al ApoM: gene regulation and effects on HDL metabolism. Trends Endocrinol Metab 2009; 20: 66-71.
71. Xia P, Gamble JR, Rye K.A., et al Tumor necrosis factor-α induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci USA 1998; 95: 14196-14201.
72. Karuna R, Park R, Othman A., et al Plasma levels of sphingosine-1- phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis 2011; 219: 855-863.
73. Diab KJ, Adamowicz JJ, Kamocki K, et al Stimulation of sphingosine 1-phosphate signaling as an alveolar cell survival strategy in emphysema. Am J Respir Crit Care Med 2010; 181: 344-352.
74. Karlsson H, Leanderson P, Tagesson C., et al Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005; 5: 1431-1445.
75. Ortiz-Muñoz G, Houard X, Martín-Ventura JL, et al. HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property. FASEB J 2009; 23: 3129-3139.
76. Holla ØL, Laerdahl JK, Strøm TB, et al. Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor. Biochem Biophys Res Commun 2011; 406: 234-238.
77. Abifadel M, Varret M, Rabès JP, et al Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154-156.
78. Abifadel M, Rabès JP, Devillers M., et al Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 2009; 30: 520-529.
79. Aung LH, Yin RX, Miao L, et al The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations. Lipids Health Dis 2011; 10: 5.
80. Cohen JC, Boerwinkle E, Mosley TH Jr, et al Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-1272.
81. Sullivan D, Olsson AG, Scott R, et al Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012; 308: 2497-2506.
82. Raal F, Scott R, Somaratne R., et al Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012; 126: 2408-2417.
83. Giugliano RP, Desai NR, Kohli P, et al Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012; 380: 2007-2017.
84. Roth EM, McKenney JM, Hanotin C, et al Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012; 367: 1891-1900.
85. Dias CS, Shaywitz AJ, Wasserman S.M., et al Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012; 60: 1888-1898.
86. Voight BF, Peloso GM, Orho-Melander M, et al Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012; 380: 572-580.
87. Barter PJ, Caulfield M, Eriksson M., et al Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122.
88. Schwartz GG, Olsson AG, Abt M, et al Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089-2099.
89. Ahnström J., Axler O, Jauhiainen M., et al Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent case-control studies. J Lipid Res 2008; 49: 1912-1917.
90. Pruitt KD, Tatusova T, Klimke W., et al NCBI Reference Sequences: current status, policy and new initiatives. Nucleic Acids Res 2009; 37: D32-D36.
91. Rudd MF, Webb EL, Matakidou A, et al Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res 2006; 16: 693-701.
92. Wang Y, Broderick P, Webb E., et al Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 2008; 40: 1407-1409.
93. Tisi GM, Conrique A, Barrett-Connor E, et al Increased high density lipoprotein cholesterol in obstructive pulmonary disease (predominant emphysematous type). Metabolism 1981; 30: 340-346.
94. Reed RM, Iacono A, DeFilippis A., et al Advanced chronic obstructive pulmonary disease is associated with high levels of high-density lipoprotein cholesterol. J Heart Lung Transplant 2011; 30: 674-678.
95. Cirillo DJ, Agrawal Y, Cassano PA Lipids and pulmonary function in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2002; 155: 842-848.
96. Ubhi BK, Riley JH, Shaw P.A., et al Metabolic profiling detects biomarkers of protein degradation in COPD patients. Eur Respir J 2012; 40: 345-355.
97. Reed RM, Hashmi S, Eberlein M., et al Impact of lung transplantation on serum lipids in COPD. Respir Med 2011; 105: 1961-1968.
98. Lovasi GS, Diez Roux AV, Hoffman EA, et al Socioeconomic status is positively associated with percent emphysema on CT scan: the MESA lung study. Acad Radiol 2011; 18: 199-204.
99. Ashraf H, Lo P, Shaker S.B., et al Short-term effect of changes in smoking behaviour on emphysema quantification by CT. Thorax 2011; 66: 55-60.